Literature DB >> 24166212

Could the complement component C4 or its fragment C4d be a marker of the more severe conditions in patients with primary Sjögren's syndrome?

Gintaras Sudzius1, Diana Mieliauskaite, Almantas Siaurys, Rita Viliene, Irena Butrimiene, Dainius Characiejus, Irena Dumalakiene.   

Abstract

Our aim is to evaluate the complement component C4 (C4) and its fragment C4d (C4d) levels, focusing on their associations with other markers of B cells' activity in patients with primary Sjögren's syndrome (pSS). Humoral factors C4, C4d, B cell-activating factor (BAFF), κ and λ free light chains (FLCs) and IgG (by immunoassay) were investigated in 58 patients with pSS and in 28 healthy controls. We observed significantly higher levels of BAFF, κ and λ FLC and IgG, and significantly lower level of C4 in pSS patients, while the level of C4d was similar in the both groups. Significantly higher levels of BAFF, κ and λ FLCs, IgG, and significantly lower C4 level were found in anti-SSA/SSB antibodies (Abs) seropositive pSS patients' group comparing with healthy controls. Level of C4d was significantly lower in anti-SSA/SSB Abs seropositive pSS patients comparing with seronegative pSS patients and healthy controls. C4d correlated with C4, anti-SSB Abs level and κ/λ ratio. Significantly higher κ FLC and IgG levels were found in anti-SSA/SSB Abs seronegative pSS patients comparing with healthy controls. Anti-SSA/SSB seropositivity in pSS patients is associated with the decreased level of C4d. These results show that C4d can be an appropriate marker of antibody response and complement activation in pSS patients with Abs, and possibly may show the more severe condition-exhaustion of C4. Further studies are required to determine whether C4d assessment could be a relevant biomarker for the more severe condition and the worse prognosis of pSS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24166212     DOI: 10.1007/s00296-013-2885-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  24 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 2.  Serum free light chain analysis.

Authors:  Matthew S Davids; Mandakolathur R Murali; David J Kuter
Journal:  Am J Hematol       Date:  2010-10       Impact factor: 10.047

3.  EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome.

Authors:  Raphaèle Seror; Philippe Ravaud; Simon J Bowman; Gabriel Baron; Athanasios Tzioufas; Elke Theander; Jacques-Eric Gottenberg; Hendrika Bootsma; Xavier Mariette; Claudio Vitali
Journal:  Ann Rheum Dis       Date:  2009-06-28       Impact factor: 19.103

4.  BAFF overexpression is associated with autoantibody production in autoimmune diseases.

Authors:  Jacques-Olivier Pers; Capucine Daridon; Valérie Devauchelle; Sandrine Jousse; Alain Saraux; Christophe Jamin; Pierre Youinou
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

5.  C4d deposition in cardiac allografts correlates with alloantibody.

Authors:  Rex Neal Smith; Nicole Brousaides; Luanda Grazette; Susan Saidman; Marc Semigran; Thomas Disalvo; Joren Madsen; G William Dec; Antonio R Perez-Atayde; A Bernard Collins
Journal:  J Heart Lung Transplant       Date:  2005-09       Impact factor: 10.247

6.  Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.

Authors:  Susan Manzi; Jeannine S Navratil; Margie J Ruffing; Chau-Ching Liu; Natalya Danchenko; Sarah E Nilson; Shanthi Krishnaswami; Dale E S King; Amy H Kao; Joseph M Ahearn
Journal:  Arthritis Rheum       Date:  2004-11

7.  Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome.

Authors:  Malin V Jonsson; Peter Szodoray; Stig Jellestad; Roland Jonsson; Kathrine Skarstein
Journal:  J Clin Immunol       Date:  2005-05       Impact factor: 8.317

8.  Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study.

Authors:  Elke Theander; Rolf Manthorpe; Lennart T H Jacobsson
Journal:  Arthritis Rheum       Date:  2004-04

Review 9.  BAFF, APRIL, TWE-PRIL: who's who?

Authors:  Capucine Daridon; Pierre Youinou; Jacques-Olivier Pers
Journal:  Autoimmun Rev       Date:  2007-06-21       Impact factor: 9.754

Review 10.  B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue.

Authors:  Arne Hansen; Peter E Lipsky; Thomas Dörner
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more
  3 in total

1.  Distribution of Peripheral Lymphocyte Populations in Primary Sjögren's Syndrome Patients.

Authors:  Gintaras Sudzius; Diana Mieliauskaite; Almantas Siaurys; Rita Viliene; Irena Butrimiene; Dainius Characiejus; Irena Dumalakiene
Journal:  J Immunol Res       Date:  2015-05-18       Impact factor: 4.818

2.  Hypocomplementemia in primary Sjogren's syndrome: association with serological, clinical features, and outcome.

Authors:  Wei Lin; Zhifei Xin; Jialan Wang; Xiuying Ren; Yixuan Liu; Liu Yang; Shaoying Guo; Yupeng Yang; Yang Li; Jingjing Cao; Xiaoran Ning; Meilu Liu; Yashuang Su; Lijun Sun; Fengxiao Zhang; Wen Zhang
Journal:  Clin Rheumatol       Date:  2022-03-29       Impact factor: 3.650

3.  Meta-Analysis of Autoimmune Regulator-Regulated Genes in Human and Murine Models: A Novel Human Model Provides Insights on the Role of Autoimmune Regulator in Regulating STAT1 and STAT1-Regulated Genes.

Authors:  Thomas R J Lovewell; Andrew J G McDonagh; Andrew G Messenger; Mimoun Azzouz; Rachid Tazi-Ahnini
Journal:  Front Immunol       Date:  2018-06-28       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.